BioSpace News Archive

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced that it signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund.

Lexogen, a transcriptomics and Next-Generation Sequencing company announced the release of the new RiboCop rRNA Depletion Kit for Yeast today.

Fuzionaire, Inc. today announced a collaborative research agreement with McGill University that will leverage the company’s proprietary alkali metal catalyst platform in creating novel heterocyclic, biologically active, silicon-containing scaffolds and new silicon-based drug candidates.

Element Biosciences, Inc. announced they are adding an industry veteran to their commercial team.

Cue Health (“Cue”) (Nasdaq: HLTH) today announced that it has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue® Flu Molecular Test for at-home and point-of-care (POC) use.

Vida Health, a leader in virtual cardiometabolic healthcare, is hiring a team of endocrinologists as it continues to expand towards higher acuity treatments.

Thryv Therapeutics Inc. is pleased to announce the appointment of Dr. Debra Odink to President and Chief Development Officer of the company and the addition of Dr. Shi Yin Foo to its Board of Directors.

The Lubrizol Corporation, a Berkshire Hathaway Company, announced that Rebecca Liebert has been named the company’s President and CEO, effective October 3, 2022.

UCB, a global biopharmaceutical company, announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology Congress in Milan, Italy, September 7-10.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 as a booster dose for active immunization against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older.